Clinical trials recruiting in Hamamatsu, Japan

Phase breakdown

Conditions recruiting in Hamamatsu, Japan

Recruiting trials in Hamamatsu, Japan

• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
  NCT06868277 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
  NCT06747949 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07196748 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
  NCT06875310 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
  NCT07196722 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
  NCT07577843 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT07577856 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
  NCT06233461 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
  NCT07361497 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
  NCT07276581 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
  NCT06958536 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
  NCT07082738 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
  NCT06975722 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
  NCT06977581 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
  NCT06935370 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
  NCT07611110 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
  NCT06023030 · Phase: Not specified · Ages: 15 Years and older · Sex: All (male and female)
• Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
  NCT05392764 · Phase: Phase 3 · Ages: 20 Years and older · Sex: All (male and female)
• Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis
  NCT07271069 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
  NCT06659393 · Phase: Not specified · Ages: 1 Year to 17 Years · Sex: All (male and female)
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female)
• Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)
  NCT07671885 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female)
• Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
  NCT07605819 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years and older · Sex: All (male and female)
• Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
  NCT07100080 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
  NCT07136116 · Phase: Not specified · Ages: 15 Years and older · Sex: All (male and female)
• Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
  NCT05712200 · Phase: Phase 3 · Ages: 65 Years and older · Sex: All (male and female)
• This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
  NCT07290803 · Phase: Not specified · Ages: 12 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Hamamatsu, Japan?

35 recruiting trials have at least one study site in Hamamatsu, Japan.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.